Additional studies that can compare the methylation status of SYCP2 in normal tissues vs. premalignant tissues will answer the question of whether the hypomethylation status of SYCP2 itself has the potential as a biomarker in the tumorigenesis of HPV-positive HNSCC. This evidence concerns the gene SYCP2 and head and neck squamous cell carcinoma.